nav-left cat-right
cat-right

Slow procedure

Slow procedure It takes 15 years on average for a drug discovery to make it to a patient’s medicine cabinet. Throughout the process, the U.S. Food and Drug Administration requires drug companies to submit applications to proceed to the next step. 1 Drug discovery and preclinical research (three to six years) – Researchers search for candidate drugs by screening chemical compounds that contain thousands or...

PharmaGap Reports That GAP-107B8 Showed Strong and...

OTTAWA, ONTARIO, Oct 27, 2009 (MARKETWIRE via COMTEX) —-PharmaGap Inc. (TSX VENTURE: GAP)(OTCBB: PHRGF) (“PharmaGap” or “the Company”) is pleased to announce highly positive results from the United States National Cancer Institute (“NCI”) 5-dose in vitro anti-cancer screen of PharmaGap drug GAP-107B8. These results confirm and extend results announced in August from the...

CytRx Unveils Clinical Development Plan for Pipeli...

Names World-Renowned Cancer Drug Expert Dr. Joseph Rubinfeld as Chief Scientific Advisor LOS ANGELES–(BUSINESS WIRE)–CytRx Corporation (NASDAQ: CYTR) today unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug candidates tamibarotene and INNO-206, which the Company believes offer the greatest mix of near-term and medium-term...

FDA Issues Public Health Advisory on Chantix

The U.S. Food and Drug Administration (FDA) today issued a Public Health Advisory to alert health care providers, patients, and caregivers to new safety warnings concerning Chantix (varenicline), a prescription medication used to help patients stop smoking. On Nov. 20, 2007, FDA issued an Early Communication to the public and health care providers that the agency was evaluating postmarketing adverse event reports on Chantix...

BIO Spent $6.6 Million on Lobbying Efforts in 2007

The Biotech Industry Organization (“BIO”) spent $6.6 Million on lobbying efforts in 2007, reported the Associated Press. BIO’s lobbying efforts last year addressed a range of issues from patent reform to generics to FDA-related issues. The Associated Press reported as follows: [BIO’s] lobbying efforts went toward cloning issues ahead of the Food and Drug Administration’s ruling that cloned meat...
Page 5 of 512345